Matteo Tozzi (Varese, Italy) recently spoke to Vascular News about the role of drug-coated balloons (DCBs) in vascular access.
The full professor of vascular surgery at the University of Insubria started the use of Aperto® OTW DCB by Cardionovum® in his vascular access practice over 10 years ago and will publish his experience with more than 600 DCBs.
While the efficacy of DCBs has been proven to be superior to that of plain balloon angioplasty for these patients, there is limited data on their economic benefit. To rectify this, Tozzi noted that he has started a collaboration that aims to assess the cost benefit of DCBs in the vascular access failure population using the data coming from his study named Aperto 600. He described the preliminary results from this as “incredible”.
Tozzi concluded that, in his opinion, DCBs should now be viewed as a “first-line” treatment for stenosis and vascular access failure in haemodialysis patients.
This video is sponsored by Cardionovum®.
